Myovant Sciences Ltd Stock News

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sumitovant Biopharma recently announced it is buying Myovant Sciences (MYOV) in a $2.9 billion deal. This is why.

BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30,

Today's market-moving news in the drugmaker sector is that Sumitomo Pharma and a subsidiary have agreed to buy out the remainder of Myovant Sciences (NYSE: MYOV ) that they don't already own. Furtherm

Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher Monday after the company announced it will be acquired by Sumitovant Biopharma for $27 per share in cash.

Shares of Myovant Sciences Ltd. MYOV, +0.95% were up 8.2% in premarket trading on Monday, the day after the company said it will be acquired by Sumitomo Pharma Co. Ltd.

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for

As Myovant overcame the odds as I forecast, Myfembree garnered another FDA approval to treat endometriosis. Subsequent to the said game-changing event, Sumitomo made an offer to acquire all outstandin

Myovant stock has rocketed in value by >100% since my last (bearish) note on the company. The main reason for the Myovant gains is an attempt by majority shareholder Sumitomo to acquire remaining shar

Myovant said "no thanks" to an acquisition offer in hopes to fetch a higher price.

Myovant Sciences Ltd (NYSE: MYOV) opened nearly 35% up on Monday after the biopharmaceutical company said it rejected a buyout proposal from its largest shareholder. Myovant is open to considering a b

Myovant Sciences Ltd (NYSE:MYOV) stock is soaring today, up 35.7% at $24.48 at last glance, after the biopharmaceutical name rejected a buyout offer from Japan-based Sumitomo Pharma.

Myovant Sciences (NYSE: MYOV ) stock is skyrocketing over 30% today on news that the British biopharmaceutical company has received a buyout offer. MYOV stock surged as much as 31% in premarket tradin

Myovant Sciences turned down a takeover bid from majority shareholder Sumitovant Biopharma on Monday, and MYOV stock skyrocketed. The post Myovant Sciences Rockets After Rejecting Lowball Sumitovant B